Press coverage about Supernus Pharmaceuticals (NASDAQ:SUPN) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 48.0906346971093 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Several research analysts have commented on SUPN shares. Stifel Nicolaus boosted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, May 25th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 24th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Jefferies Financial Group boosted their price objective on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $54.09.

Shares of NASDAQ:SUPN opened at $44.80 on Friday. The firm has a market cap of $2.41 billion, a PE ratio of 35.56 and a beta of 0.97. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54. Supernus Pharmaceuticals has a 52-week low of $33.30 and a 52-week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The company had revenue of $99.54 million during the quarter, compared to the consensus estimate of $101.01 million. sell-side analysts anticipate that Supernus Pharmaceuticals will post 1.91 EPS for the current year.

In related news, VP Padmanabh P. Bhatt sold 7,795 shares of the business’s stock in a transaction on Friday, June 29th. The shares were sold at an average price of $59.92, for a total value of $467,076.40. Following the sale, the vice president now owns 7,795 shares of the company’s stock, valued at $467,076.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 7,205 shares of the business’s stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total transaction of $432,300.00. Following the completion of the sale, the vice president now directly owns 14,705 shares in the company, valued at approximately $882,300. The disclosure for this sale can be found here. In the last three months, insiders sold 110,000 shares of company stock worth $6,144,826. 6.20% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: Google Finance Portfolio Workaround

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.